Regeneron Reports Third Quarter 2018 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Regeneron Pharma (REGN) PT Raised to $315 at Barclays
November 7, 2018 7:34 AM ESTBarclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 (from $305.00) while maintaining a Underweight rating following the company's 3Q earnings report.
Meacham thought Regenerons 3Q results were very good (+$22M top-line; +$0.70 bottom-line), and while Barclays continues to... More
Regeneron (REGN) Tops Q3 EPS by 69c, Revenues Beat
November 6, 2018 6:37 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $5.87, $0.69 better than the analyst estimate of $5.18. Revenue for the quarter came in at $1.66 billion versus the consensus estimate of $1.64 billion.
Third quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 7% to $1.02 billion versus third quarter 2017, and third quarter 2018 EYLEA global net sales(1) increased 11% to $1.68 billion versus third quarter 2017U.S. launch of Libtayo® (cemiplimab-rwlc) Injection for the... More